Qlaris Bio, Inc.

Dedham, MA · Founded 2019 · CIK 0001786717 · Biotech · Private

Biotechnology therapeutics for ophthalmic diseases, specifically QLS-111 for lowering intraocular pressure in glaucoma

qlaris.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$42M
4 Form D · Jun 2026
4 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$8,164,654
Private capital raisedForm D · SEC$24,032,554
Private capital raisedForm D · SEC$5,641,600
Private capital raisedForm D · SEC$3,946,659
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1200DMC BIOTECHNOLOGIES, INC.—$47M
1201Obatala Sciences, Inc.—$200K
1202Oncorus, Inc.—$47M
1203Qlaris Bio, Inc.—$42M
1204PLAKOUS THERAPEUTICS, INC.—$185K
1205ADIAL PHARMACEUTICALS, INC.—$38M
1206FORWARD DEFENSE, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • Andrew DanielsenDirector
  • Andrew DanielsonDirector
  • Adrienne GravesDirector
  • Frederic GuerardDirector · Executive Officer
  • Thurein HtooDirector · Executive Officer
  • Ron HuntDirector
  • Ronald HuntDirector
  • Wende HuttonDirector
  • Robert WarnerDirector
  • Barbara WirostkoExecutive Officer

Patents

USPTO · 0 granted of 2
  • Topical Ocular Delivery Of Cromakalimapplication
  • Compositions And Methods For Extended Release Cromakalim Therapyapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.